BRAF and neoplasm: In addition, only one patient whose tumor was originally classified as BRAF wild-type, and subsequently flagged as BRAF mutation-positive by the cell-free assay, went on to receive and benefit from targeted therapy with cobimetinib plus vemurafenib.